Form 4: Neumora Therapeutics Director Paul L. Berns Reports Stock Sale to Cover Tax Obligations

Paul L. Berns, a director and officer of Neumora Therapeutics, sold shares of common stock on February 18, 2025, to cover withholding tax obligations related to vesting restricted stock units.

Summary

• On February 18, 2025, Paul L. Berns, a director and officer (Chief Executive Officer and Chairman of the Board) of Neumora Therapeutics, sold 13,871 shares of common stock.
• The sale was executed at a weighted average price of $1.6919 per share, with individual trades ranging from $1.66 to $1.745.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on April 19, 2024.
• The purpose of the sale was to cover withholding tax obligations associated with the vesting of restricted stock units.
• Following the transaction, Berns directly owns 7,405,004 shares of Neumora Therapeutics common stock.
• Berns also indirectly owns 133,097 shares through each of the LULU TRUST OF 2024 FBO AB, LULU TRUST OF 2024 FBO OB and LULU TRUST OF 2024 FBO HB.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure related to insider trading activity. It is common for executives to sell shares to cover tax obligations, especially after stock options or restricted stock units vest. The existence of a 10b5-1 plan suggests the insider is following best practices to avoid accusations of illegal insider trading.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the relatively small number of shares sold compared to the total outstanding shares.

Key Dates

Keywords

Form 4, Neumora Therapeutics, NMRA, Paul L. Berns, Stock Sale, Rule 10b5-1, Insider Trading, Beneficial Ownership, Director, Officer